High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial.
Alemany A, Millat-Martinez P, Corbacho-Monné M, Malchair P, Ouchi D, Ruiz-Comellas A, Ramírez-Morros A, Rodríguez Codina J, Amado Simon R, Videla S, Costes G, Capdevila-Jáuregui M, Torrano-Soler P, San José A, Bonet Papell G, Puig J, Otero A, Ruibal Suarez JC, Zarauza Pellejero A, Llopis Roca F, Rodriguez Cortez O, Garcia Garcia V, Vidal-Alaball J, Millan A, Contreras E, Grifols JR, Ancochea À, Galvan-Femenia I, Piccolo Ferreira F, Bonet M, Cantoni J, Prat N, Ara J, Forcada Arcarons A, Farré M, Pradenas E, Blanco J, Àngel Rodriguez-Arias M, Fernández Rivas G, Marks M, Bassat Q, Blanco I, Baro B, Clotet B, Mitjà O; CONV-ERT Group.
Alemany A, et al. Among authors: capdevila jauregui m.
Lancet Respir Med. 2022 Mar;10(3):278-288. doi: 10.1016/S2213-2600(21)00545-2. Epub 2022 Feb 9.
Lancet Respir Med. 2022.
PMID: 35150610
Free PMC article.
Clinical Trial.